芎黄合剂治疗重症肺炎合并胃肠功能障碍临床观察

发布时间：2018-04-21 17:29

本文选题：芎黄合剂 + 重症肺炎　；参考：《中国中西医结合杂志》2017年08期

【摘要】：目的探讨芎黄合剂治疗重症肺炎合并胃肠功能障碍患者的临床疗效。方法将60例重症肺炎合并胃肠功能障碍的患者随机分为对照组和芎黄合剂组,每组30例。对照组采用西医常规治疗,芎黄合剂组在对照组治疗的基础上加用芎黄合剂,疗程均为14 d。比较治疗前及治疗第7、14 d两组炎症因子水平(血清CRP、PCT、IL-6和IL-8)、临床肺部感染评分(CPIS)、胃肠功能障碍评分(GIDS)及第28 d死亡率。结果治疗后第7、14 d两组患者炎症水平、CPIS及GIDS均较本组治疗前明显下降(P0.05,P0.01);第7、14 d芎黄合剂组的上述指标较对照组同期降低(P0.05,P0.01);第28 d芎黄合剂组病死率[6.7%(2/30)]低于对照组[16.7%(5/30)],但两者比较差异无统计学意义(P0.05)。结论芎黄合剂能降低重症肺炎合并胃肠功能障碍患者炎症水平,促进患者胃肠功能恢复。
[Abstract]:Objective to investigate the clinical effect of Xiong Huang mixture in treating severe pneumonia with gastrointestinal dysfunction. Methods 60 patients with severe pneumonia complicated with gastrointestinal dysfunction were randomly divided into control group and Xiong Huang mixture group with 30 cases in each group. The control group was treated with routine western medicine, the control group was treated with Xiong Huang mixture on the basis of the control group, and the course of treatment was 14 days. The levels of inflammatory cytokines (serum CRPpPCTU IL-6 and IL-8, clinical pulmonary infection score, GIDSs) and 28 day mortality were compared between the two groups before treatment and at day 7 and 14 after treatment. Results the inflammatory levels of CPIS and GIDS in both groups were significantly lower than those before treatment, the above indexes in Xionghuang mixture group were significantly lower than those in control group on the 7th day of 14th day compared with the control group, and the fatality rate of Xiong Huang mixture group on the 28th day was lower than that of the control group. [16.7% / 30], but there was no significant difference between the two groups (P 0.05). Conclusion Xiong Huang mixture can reduce the inflammatory level and promote the recovery of gastrointestinal function in patients with severe pneumonia complicated with gastrointestinal dysfunction.
【作者单位】：南京市中医院重症医学科;
【基金】：南京市医学科技发展项目(No.YKK14144)
【分类号】：R259

【相似文献】